This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus, Inc. Extends Loan Facility With Comerica Bank

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2012 (GLOBE NEWSWIRE) -- diaDexus, Inc. (OTCQB:DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced that it has entered into an agreement to modify the terms of its existing $5 million loan facility with Comerica Bank. The modified terms of the agreement extend the interest-only payment period for an additional 12 months through September 23, 2013. The modification also reduces the monthly principal payments offset by an increase in the final payment on September 23, 2016.

Brian Ward, Ph.D., President and Chief Executive Officer of diaDexus, Inc., commented, "The successful restructuring of this loan underscores our long partnership with Comerica and the continued strength of our business. We achieved solid financial results in the second quarter of 2012, including record sales and modest cash use and we remain confident in our ability to drive growth through our leveraged sales model with our cardiovascular specialty laboratory partners."

Jeff Chapman, SVP and Head of Life Sciences at Comerica, said, "diaDexus has made great strides with eight consecutive quarters of year-over-year revenue growth from expanding the adoption of the PLAC test, which has the potential to help physicians reduce the risk of cardiovascular disease for their patients."

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA 2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA 2 Activity on-site. For more information, please visit the company's website at www.diaDexus.com.

About Comerica Bank's Technology and Life Sciences Division

Comerica Bank's Technology and Life Sciences Division is one of the nation's leading technology banking practices, offering a wide range of financial services tailored to corporate customers, entrepreneurs and professionals. Veteran bankers provide credit and financial services and products to young, growing, professionally backed technology and life sciences companies, as well as their more mature counterparts. The Technology and Life Sciences Division serves all major U.S. technology centers from offices coast-to-coast and its headquarters in Palo Alto, California. Comerica Bank is a subsidiary of Comerica Incorporated (NYSE:CMA), a financial services company that is among the 25 largest U.S. banking companies. For more information, visit www.comerica.com .

CONTACT: Company Contacts:
         diaDexus, Inc.
         Brian E. Ward, Ph.D., CEO
         Jean-Frederic Viret, Ph.D., CFO
         650-246-6400
         investors.diadexus.com
         
         Investor Relations:
         The Ruth Group
         Nick Laudico / Zack Kubow
         646-536-7030 / 7020
         nlaudico@theruthgroup.com
         zkubow@theruthgroup.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs